Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07218926 · ClinicalTrials.gov registry record · Phase 3

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

A Phase 3 study of Gastrointestinal Neoplasms, sponsored by GlaxoSmithKline.

Recruiting
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT07218926 is a Phase 3 study of Gastrointestinal Neoplasms that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 450 participants, below the 929-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07218926, a Phase 3 study of Gastrointestinal Neoplasms, is actively recruiting participants, sponsored by GlaxoSmithKline.

RECRUITING
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.

Conditions Studied

Gastrointestinal Neoplasms

Interventions

  • DRUG Sunitinib
  • DRUG IDRX-42

Study Locations (20)

Other

  • GSK Investigational Site - Chiba
  • GSK Investigational Site - Ehime
  • GSK Investigational Site - Fukuoka
  • GSK Investigational Site - Hokkaido
  • GSK Investigational Site - Kanagawa
  • GSK Investigational Site - Osaka
  • GSK Investigational Site - Tokyo
  • GSK Investigational Site - Changhua
  • GSK Investigational Site - Kaohsiung City
  • GSK Investigational Site - Taipei
  • GSK Investigational Site - London
  • GSK Investigational Site - Manchester

Massachusetts

  • GSK Investigational Site - Boston

Nebraska

  • GSK Investigational Site - Omaha

New York

  • GSK Investigational Site - New York

Pennsylvania

  • GSK Investigational Site - Philadelphia

Tennessee

  • GSK Investigational Site - Knoxville

Texas

  • GSK Investigational Site - Houston

Washington

  • GSK Investigational Site - Tacoma

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2025-12-03
Est. Completion 2030-11-29
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07218926

The ClinicalTrials.gov registry entry for NCT07218926 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 929-participant average among 12 other Gastrointestinal Neoplasms trials with a reported enrollment target (52% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastrointestinal Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.

NCT07218926 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Massachusetts, Nebraska.

Frequently Asked Questions

What is clinical trial NCT07218926 about?

NCT07218926 is a clinical study titled "A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy". The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe f...

What is the current status of trial NCT07218926?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2025-12-03. Estimated completion is 2030-11-29.

What conditions does trial NCT07218926 study?

This clinical trial studies the following conditions: Gastrointestinal Neoplasms.

What interventions are being tested in trial NCT07218926?

The interventions under investigation include: Sunitinib (DRUG), IDRX-42 (DRUG).

Who is sponsoring clinical trial NCT07218926?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07218926 being conducted?

This trial has 20 study locations across Massachusetts, Nebraska, New York, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Neoplasms

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.